ZURA Zura Bio Ltd
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1855644 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-43.7%
TTM EPS YoY-70.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-65.4%
ROA-55.2%
ROIC (approx.)-164.3%
Asset turnover—
Leverage & solvency
Liabilities / assets8.7%
Debt / equity0.00x
Current ratio11.29x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.24x
Accruals ratio-42.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $19.49M | $20.71M | $14.75M | $10.96M | $11.95M | $8.70M | $10.47M | $9.24M |
| SG&A expense | $9.28M | $8.62M | $10.75M | $7.46M | $7.57M | $9.36M | $8.78M | $6.49M |
| Operating income | -$28.77M | -$29.32M | -$25.50M | -$18.41M | -$19.52M | -$18.06M | -$19.25M | -$15.73M |
| Pretax income | -$27.05M | -$26.39M | -$24.22M | -$17.18M | -$18.04M | -$15.99M | -$17.44M | -$13.62M |
| Income tax | -$1.22M | -$81,000 | $0 | — | $0 | $0 | $0 | — |
| Net income | -$25.82M | -$26.30M | -$24.22M | -$17.18M | -$18.04M | -$15.99M | -$17.44M | -$13.62M |
| EBITDA | -$28.77M | -$29.34M | -$25.48M | -$18.40M | -$19.52M | -$18.05M | -$19.25M | -$15.73M |
| EPS (basic) | -0.20 | -0.21 | -0.22 | — | -0.21 | -0.17 | -0.19 | — |
| EPS (diluted) | -0.20 | -0.21 | -0.22 | — | -0.21 | -0.17 | -0.19 | — |
| Weighted avg. shares (diluted) | 127.71M | 126.80M | 112.22M | — | 94.56M | 94.29M | 92.96M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $187.65M | $205.13M | $225.59M | $109.41M | $139,017 | $154,490 | $170.57M | $176,498 |
| Current assets | $191.59M | $210.50M | $227.00M | $112.31M | $142.29M | $156.99M | $171.69M | $178.74M |
| PP&E, net | $153,000 | $149,000 | $125,000 | $126,000 | $131,000 | $122,000 | $106,000 | $91,000 |
| Total assets | $194.63M | $213.40M | $228.64M | $113.95M | $143.94M | $157.81M | $172.50M | $179.53M |
| Current liabilities | $16.97M | $16.32M | $11.74M | $12.41M | $25.49M | $18.70M | $21.09M | $19.51M |
| Total liabilities | $16.97M | $16.32M | $11.74M | $12.41M | $25.49M | $18.70M | $21.09M | $19.51M |
| Shareholders' equity | $177.66M | $197.09M | $216.90M | $101.54M | $108.24M | $125.91M | $138.20M | $146.81M |
| Shares outstanding | 96.31M | 95.42M | 94.88M | 73.68M | 65.02M | 62.06M | 68.37M | 65.30M |
| Cash flow statement | ||||||||
| Operating cash flow | -$19,498 | $18.88M | -$18.92M | -$22.28M | -$15,444 | -$16.03M | -$11.06M | -$10.82M |
| Capital expenditure | $36 | -$12,963 | $13,000 | $17,000 | $32 | $15,000 | $49,000 | $45,000 |
| Free cash flow | -$19,534 | $18.90M | -$18.94M | -$22.30M | -$15,476 | -$16.05M | -$11.11M | -$10.87M |
| Investing cash flow | -$36 | $12,963 | -$13,000 | -$17,000 | -$32 | -$15,000 | -$49,000 | -$45,000 |
| Financing cash flow | $2,052 | -$134.99M | $135.12M | -$7.32M | $3 | -$34,000 | $5.18M | -$854,000 |
| Depreciation & amortization | $20 | -$15,968 | $16,000 | $15,000 | $14 | $11,000 | $9,000 | $5,000 |
| Stock-based compensation | $5.32M | $4.46M | $5.01M | $2.58M | $2.38M | $3.73M | $3.64M | $2.82M |
Free plan shows the latest 8 periods; Pro shows all 21 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.